Israel Ora, Mekel Michal, Bar-Shalom Rachel, Epelbaum Ron, Hermony Nirit, Haim Nissim, Dann Eldad J, Frenkel Alex, Ben-Arush Myriam, Gaitini Diana
Department of Nuclear Medicine, Rambam Medical Center, Haifa, Israel.
J Nucl Med. 2002 Oct;43(10):1295-303.
The purpose of the present study was to evaluate the role of 67Ga scintigraphy and CT in treatment monitoring of bone lymphoma.
Forty-four lymphoma patients with 91 sites of bone involvement were evaluated. Eight patients had Hodgkin's disease, and 36 patients had non-Hodgkin's lymphoma. Thirteen patients had primary lymphoma of the bone, and 31 patients had secondary lymphoma of the skeleton. 67Ga and CT studies were performed at baseline, during and at the end of treatment, and during follow-up. Positive 67Ga studies showed abnormal uptake in sites of lymphomatous involvement. Positive CT studies showed lesions with patterns of osteolysis, patterns of osteosclerosis, or a mixed pattern. A negative 67Ga or CT study showed disappearance of all lymphoma-related abnormalities. The sensitivity and specificity of 67Ga scintigraphy at presentation were calculated. Patterns of bone lymphoma on CT and their treatment-related changes were analyzed and recorded. Freedom-from-progression (FFP) curves were used to determine the prognostic value of positive and negative 67Ga and CT findings for predicting outcome after treatment.
The sensitivity of 67Ga for diagnosis of bone lymphoma was 93%, and the specificity was 91%. A CT pattern of osteolysis was seen in 70% of skeletal disease sites at diagnosis and in 21% during follow-up. Osteosclerosis was present in 23% of sites at diagnosis and in 38% during follow-up. 67Ga findings became negative in 25% of patients during treatment, whereas only 1 patient showed negative CT findings. Forty-two percent of patients had negative 67Ga findings at the end of treatment, compared with 18% who had negative CT findings. Sixty-one percent of patients had negative 67Ga findings during follow-up, compared with 21% who had negative CT findings. A statistically significant difference in FFP was found between patients with positive and negative 67Ga findings at all evaluated time points. No statistically significant difference in FFP was found at any time point between patients with positive and negative CT findings.
67Ga scintigraphy has a high sensitivity and specificity for diagnosis of bone lymphoma. Bone lymphoma may show osteosclerotic and osteolytic CT patterns at diagnosis, during treatment, and after treatment. In most patients, CT studies do not become negative even 1 y after treatment. 67Ga scintigraphy, however, may be used as a predictor of long-term outcome in patients with lymphoma of the skeleton.
本研究的目的是评估67Ga闪烁扫描和CT在骨淋巴瘤治疗监测中的作用。
对44例有91处骨受累部位的淋巴瘤患者进行评估。8例为霍奇金病患者,36例为非霍奇金淋巴瘤患者。13例为原发性骨淋巴瘤患者,31例为继发性骨骼淋巴瘤患者。在基线期、治疗期间、治疗结束时及随访期间进行67Ga和CT检查。67Ga检查阳性显示淋巴瘤受累部位有异常摄取。CT检查阳性显示有溶骨型、骨硬化型或混合型病变。67Ga或CT检查阴性显示所有淋巴瘤相关异常消失。计算67Ga闪烁扫描在初诊时的敏感性和特异性。分析并记录CT上骨淋巴瘤的表现及其与治疗相关的变化。采用无进展生存期(FFP)曲线来确定67Ga和CT检查阳性及阴性结果对预测治疗后结局的预后价值。
67Ga诊断骨淋巴瘤的敏感性为93%,特异性为91%。诊断时70%的骨骼病变部位表现为CT溶骨型,随访期间为21%。诊断时23%的部位有骨硬化,随访期间为38%。25%的患者在治疗期间67Ga检查结果转为阴性,而只有1例患者CT检查结果为阴性。治疗结束时42%的患者67Ga检查结果为阴性,而CT检查结果为阴性的患者为18%。随访期间61%的患者67Ga检查结果为阴性,而CT检查结果为阴性的患者为21%。在所有评估时间点,67Ga检查结果阳性和阴性的患者之间FFP有统计学显著差异。CT检查结果阳性和阴性的患者在任何时间点FFP均无统计学显著差异。
67Ga闪烁扫描对骨淋巴瘤的诊断具有高敏感性和特异性。骨淋巴瘤在诊断、治疗期间及治疗后可能表现为CT骨硬化型和溶骨型。在大多数患者中,即使在治疗1年后CT检查结果仍未转为阴性。然而,67Ga闪烁扫描可作为骨骼淋巴瘤患者长期结局的预测指标。